European AIDS Treatment Group·3 min read·hard
[AIDS 2026] MedPage Today: Long-acting lenacapavir still delivered effective HIV PrEP after a year
H
https://www.facebook.com/EuropeanAIDSTreatmentGroup![[AIDS 2026] MedPage Today: Long-acting lenacapavir still delivered effective HIV PrEP after a year](/api/imagekit?u=https%3A%2F%2Fwww.eatg.org%2Fwp-content%2Fuploads%2F2023%2F12%2F1674900.jpg&w=3840&q=75)
✦AI Summary
Clinical trial extensions for the injectable HIV prevention drug lenacapavir have shown high efficacy with almost no new infections reported over a year. The study included diverse populations across South Africa, Uganda, and other regions.
Only one person has developed a new HIV infection during a year-long extension of the landmark PURPOSE 1 and PURPOSE 2 trials testing twice-yearly injectable lenacapavir (Yeztugo) for PrEP, according to twin open-label extensions.
healthscience
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in